Thus, while combination therapies with drugs that increase gastrin levels are promising avenues to improve glycemic control in T2DM, possibly through increasing β-cell mass, further studies must be conducted to discover novel combination therapies with gastrin to treat T1DM. The gene discussed is GAST; the disease is type 1 diabetes mellitus.